Literature DB >> 18773227

Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.

Snezana Susnjar1, Snezana M Bosnjak, Sinisa Radulovic.   

Abstract

BACKGROUND: Skin toxicity has recently been recognized as a dose-limiting toxicity of antineoplastic therapy. DISCUSSION: We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18773227     DOI： 10.1007/s00520-008-0495-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  21 in total

1.  Clinical picture: nail changes secondary to docetaxel.

Authors:  G Wasner; F Hilpert; R Baron; J Pfisterer
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

2.  Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading?

Authors:  Simon Spazzapan; Diana Crivellari; Davide Lombardi; Cristina Scuderi; Maria Donatella Magri; Andrea Veronesi; Alessandro Gatti
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

3.  A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.

Authors:  M A Villalona-Calero; J L Blum; S E Jones; S Diab; R Elledge; P Khoury; D Von Hoff; M Kraynak; J Moczygemba; P Kromelis; T Griffin; E K Rowinsky
Journal:  Ann Oncol       Date:  2001-05       Impact factor: 32.976

Review 4.  Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature.

Authors:  S Hussain; D N Anderson; M E Salvatti; B Adamson; M McManus; A S Braverman
Journal:  Cancer       Date:  2000-05-15       Impact factor: 6.860

5.  Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.

Authors:  J L Blum; V Dieras; P M Lo Russo; J Horton; O Rutman; A Buzdar; B Osterwalder
Journal:  Cancer       Date:  2001-10-01       Impact factor: 6.860

6.  Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL.

Authors:  F Di Costanzo; S Gasperoni; P Papaldo; D Bilancia; L Manzione; E Landucci; F Mazzoni; F Cognetti
Journal:  Ann Oncol       Date:  2005-11-10       Impact factor: 32.976

7.  Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.

Authors:  Joanne L Blum; E Claire Dees; Aparna Chacko; Lisa Doane; Sukumar Ethirajan; Judith Hopkins; Richard McMahon; Suzan Merten; Angel Negron; Marcus Neubauer; Des Ilegbodu; Kristi A Boehm; Lina Asmar; Joyce A O'Shaughnessy
Journal:  J Clin Oncol       Date:  2006-08-22       Impact factor: 44.544

8.  Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.

Authors:  E A Perez; C L Vogel; D H Irwin; J J Kirshner; R Patel
Journal:  J Clin Oncol       Date:  2001-11-15       Impact factor: 44.544

9.  Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.

Authors:  A J ten Tije; C H Smorenburg; C Seynaeve; A Sparreboom; K L C Schothorst; L G M Kerkhofs; L G P M van Reisen; G Stoter; M Bontenbal; J Verweij
Journal:  Eur J Cancer       Date:  2004-02       Impact factor: 9.162

Review 10.  Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

Authors:  A D Seidman; C A Hudis; J Albanell; J Albanel; W Tong; I Tepler; V Currie; M E Moynahan; M Theodoulou; M Gollub; J Baselga; L Norton
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544
View more
  1 in total

Review 1.  Dermatological adverse events with taxane chemotherapy.

Authors:  Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture
Journal:  Eur J Dermatol       Date:  2016-10-01       Impact factor: 3.328
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.